Awards for January 2014

Federal Awards

January Awards

Alto, Neal (Fellow L. Reddick), NIH, Bacterial avoidance of innate immune detection, $53,942; Aroumougame, Asaithamby, NASA, Mechanism of Clustered DNA Double-strand Break Repair in Response to HZE Particles in Human Cells, $384,788; Brekken, Rolf, NIH, Axl as Target for Therapy of Pancreatic Cancer, $155,622; Brekken, Rolf (Fellow K. Aguilera), NIH, SPARC as Regulator of Collagen Signaling in Pancreatic Cancer - Diversity Fellowship, $29,597; Brown, Sherwood, NIH, Reversing Corticosteroid-Induced Memory Impairment, $247,921; Burma, Sandeep, NIH, Molecular Mechanisms of GBM Radioresistance and Strategies for Radiosensitization, $296,933;

Cannon, Carolyn, Washington Univ in St. Louis/NIH, Integrated Nanosystems for Diagnosis and Therapy, $235,234; Casey, Brian, George Washington Univ/NIH, Eunice Kennedy Schriver NICHD-MEFU Clinical Ctr Agmt-Capitation payments, $235,092; Castrillon, Diego, NIH, Mouse Models and Translational Studies of Endometrial Cancer, $288,024; Chen, Chuo, NIH, Asymmetric Synthesis of Biologically Active Marine Natural Products, $269,838; Chin, Kelly, NIH, Serotonin Transporter in Pulmonary Arterial Hypertension, $128,589; Chook, Yuh Min, NIH, Structures and Mechanisms of Nuclear Import and Export, $300,139;

Farrar, John, NIH, Type 1 Interferon-Regulated T Helper Development, $318,755; Farrar, John, NIH, Type 1 Interferon-Regulated T Helper Development - Diversity Supplement, $58,933; Frohman, Elliot, Southern Methodist Univ/NIH, Dynamic Blood Pressure Control and Orthostatic Tolerance in Individuals with MS at Rest and During Heat Stress, $29,565; Gatson, Joshua, Meso Scale Diagnostics/U.S. DOD, Fieldable Multiplex Test for TBI Assessment, $96,462; Greene, Robert, Brandeis Univ/NIH, Role of NMDA Receptors in Awake-State Thalamocortical Slow Waves, $25,432; Greilich, Philip, New England Res Insts/NIH, Transfusion MED/Hemostasis Clinical Trials Network (TMH), $20,300;

Gumbo, Tawanda, Univ of Pennsylvania/NIH, Immune Activation and Isoniazid Metabolism in HIV/TB, $46,740; Haley, Robert, Univ of Texas at Dallas/NIH, Integrating Multimodal Brain Imaging Data to Assess Subtle Cognitive Impairment, $7,295; Hall, Christiana, Univ of Cincinnati/NIH, Ethnic/Racial Variation in Intracerebral Hemorrhage (ERICH), $56,220; Hansen, Eric, NIH, Haemophilus Ducreyi Inhibits Phagocytosis, $357,750; Hedayati, Susan, NIH, Randomized Trial of Sertraline Treatment of Depression in Chronic Kidney Disease, $311,243; Hendrixson, David, NIH, Structural Components of Campylobacter jejuni Polar Flagellar Motor, $125,199;

Herz, Joachim, NIH, Metabolism of the VLDL Receptor and ApoE Receptor 2, $357,750; Hobbs, Helen, NIH, Role of ABCG5 and ABCG8 in Sterol Metabolism, $421,609; Hsia, Connie, Duke Univ/NIH, LRRC: Sense and Antisense Erythropoietin Receptor Transcripts and Proteins; Administrative, $120,051; Jain, Mamta, Inst for Clinical Res Inc/NIH, TO3; START "Strategic Timing of Antiretroviral Therapy"; INSIGHT Task Order 3, $279,500; Jain, Mamta, Inst for Clinical Res Inc/NIH, TO6; FLU IVIG "Anti-Influenza Hyperimmune Intravenous Immunoglobulin Study"; INSIGHT Task Order 6, $240,105; Johnson, Mark, Yale Univ/NIH, Insulin Resistance Intervention after Stroke (IRIS) Trial, $312;

Journeycake, Janna, Univ of Texas Hlth Sci Ctr at Houston/HRSA, Hemophilia Treatment Centers (SPRANS), $25,423; Kennard, Beth, NIH, 2/2 Brief Intervention for Suicide Risk Reduction in High Risk Adolescents, $198,750; Kohler, Jennifer (Fellow A. Wands), NIH, Photocrosslinking Characterization of Heat-Labile Toxin Glycoreceptors, $53,942; Macdonald, Raymond, Vanderbilt Univ/NIH, Architecture and Communication Controlling the Efficient Generation of Beta Cells (VUMC37153), $273,973; Martinez, Elisabeth, NIH, Characterization of Biological Activities of Novel Epigenetic Modulators, $300,826; Martinez, Elisabeth, NIH, Characterization of Biological Activities of Novel Epigenetic Modulators - Diversity Supplement, $123,066;

Mason, Ralph, Baylor Univ/NIH, Chemotherapeutic Agents with Enhanced Selectivity for Tumor Microenvironment, $30,967; Mendell, Joshua, Johns Hopkins Univ/NIH, Functional Annotation of Pancreatic Cancer Genome, $138,220; Miles, Darryl, Univ of Pittsburgh/NIH, Approached and Decisions for Acute Pediatric TBI (ADAPT Study), $3,000; Morrison, Sean, NIH, Regulation of protein synthesis in stem cells, $276,660; Morrison, Sean, NIH, Regulation of Stem Cell Aging, $11,510; Morrison, Sean, NIH, Regulation of Stem Cell Aging, $10,877;

Norgard, Michael, NIH, RpoN-RpoS Regulatory Pathway in Borrellia Burgdorferi, $354,173; North, Carol, Washington Univ in St. Louis/NIH, Multi-Disciplinary Evaluation of Chronic Pelvic Pain Syndrome, $7,155; Perez-Fontan, Julio, NIH, Antecedants Sequelae of Childhood Onset Disease, $432,000; Phelan, Herbert, Univ of Pittsburgh/U.S. DOD, PreHOSP Air Medical Plasma (PAMPer) Trial, $90,685; Raskin, Philip, George Washington Univ/NIH, Glycemia Reduction Approaches for Diabetes: Comparative Effectiveness (GRADE), $279,422; Rogers, Zora, NIH, Baby HUG Follow-Up Study II, $170,057; Rogers, Zora, Feinstein Inst for Med Res/U.S. DOD, A Pilot, Phase I/II Study of the Amino Acid Leucine in the Treatment of Patients with Transfusion-Dependent Diamond Blackfan Anemia, $2,930;

Sanchez, Pablo, RTI Internatl/NIH, NICHD Neonatal Research Network Capitation Funding, $29,116; Schmid, Sandra, NIH, Clathrin Coated Vesicle Cycle, $406,992; Seemann, Joachim, NIH, Cell Cycle Regulation of Golgi Membrane Dynamics, $186,200; Self, David, NIH, Role of Endogenous Opiate Systems in Cocaine Relapse After Long-Term Abstinence, $308,387; Self, David, Mt. Sinai School of Med/NIH, Neuroadaptations in Drug Self-Administration and Relapse, $298,284; Shaul, Philip, Univ of Illinois/NIH, Novel Ligands and Mechanisms to Achieve Selective Nuclear Receptor Activity, $111,352;

Sherry, Dean, NIH, PARACEST Agents for Molecular Imaging of Cancer by MRI, $241,179; Shiloh, Michael, NIH, Identification of novel M. tuberculosis secreted effector proteins, $175,808; Soesbe, Todd, U.S. Dept of Defense, Using T2-exchange from Ln3+DOTA-based Chelates for Contrast-Enhanced Molecular Imaging of Prostate Cancer with MRI, $119,250; Stull, James, Univ of Texas Hlth Sci Ctr at Houston/NIH, ACTA2, MYH11 and MYLK Mutations Affecting Smooth Muscle Contraction, $390,475; Terman, Jonathan, NIH, Molecular Mechanisms of Semaphorin/Plexin-Mediated Cytoskeletal Reorganization, $313,031; Toto, Robert, Stanford Univ/NIH, SPRINT MIND the Kidneys, $77,398;

Vongpatanasin, Wanpen, NIH, Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension, $495,896; Westover, Arthur, NIH, Cardiovascular Risks of Prescription Amphetamine Use in National Veterans Study, $171,155; Wright, Tracey, Duke Univ Med Ctr/NIH, Mechanisms of Beta Cell Responses in Autoimmune Disease, $97,198; Yan, Nan, NIH, HIV Subversion of Innate Immunity, $357,750; Yarovinsky, Felix, NIH, Cellular and Molecular Mechanisms of Host Resistance to Toxoplasma Gondii, $354,173; Zhang, Chengcheng, NIH, Role of Inhibitory Receptors in Leukemia Development, $296,933.

Non-Federal Awards

Altschuler, Steven (Fellow C. Thorne), Amer Cancer Soc, Mechanisms of Homeostasis and Drug Resistance in Colonic Epithelial Cells, $61,500; Berry, Jarett, Amer Heart Assoc, Long-Term Implications of the AHA 2020 Strategic Impact Goals for Medicare Costs, $70,000; Borek, Dominika, Amer Heart Assoc, Mapping of Somatic Mitochondrial DNA Mutations in Aging Heart, $70,000; Bourland, Christina, Texas Pediatric Soc Fdn, Community Pediatrics and Advocacy Training Program at UT Southwestern Pediatric Residency Program, $2,500; Cannon, Carolyn, Cystic Fibrosis Fdn, Cystic Fibrosis Therapeutics Development Center, $54,664; Debose-Boyd, Russell (Fellow R. Faulkner), Amer Heart Assoc, Establishing Drosophila as a model system to study ER-associated degradation of HMG CoA reductase and Insig-1, $25,000;

Graff, Jonathan (Fellow Y. Jiang), Amer Heart Assoc, Role of insulin and IGF-1 receptor signaling in adipose stem cell function and maintenance, $46,796; Gumbo, Tawanda, Critical Path Inst/Gates Fdn, Hollow Fiber System Sub-Grant, Critical Path to TB Drug Regimen (HFS-TB), $718,700; Herz, Joachim, Univ of California, San Francisco, Consortium for Frontotemporal Dementia Research (MPI), $128,500; Hofmann, Sandra, Uniting Against Lung Cancer, Protein Palmitoyltransferase DHHC5 as Therapeutic Target for Lung Cancer, $50,000; Iscla, Irene, Amer Heart Assoc, Novel Approach for Study of Function-Structure Relationships of Channels Involved in Ischemia and Angiogenesis, $77,000; Jacobe, Heidi, Scleroderma Fdn, Something New Under the Sun: Trial of UVA 1 Phototherapy in Localized Scleroderma, $50,000;

Jain, Raksha, Cystic Fibrosis Fdn, Therapeutics Development Center, $54,664; Jain, Raksha, Seattle Children’s Res Inst/Cystic Fibrosis Fdn, Study of Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis Patients, $43,440; Kelly, Nancy, Texas Pediatric Soc/Amer Acad of Pediatrics, Healthy Active Living, $14,306; Knudsen, Erik, Thomas Jefferson Univ/Pfizer Inc, Determinants of response to CDK4/6 Inhibitors in melanoma, $69,108; McAdams, Carrie, Brain & Behavior Res Fdn/NARSAD, Neurodevelopment of Identity in Adolescent Anorexia Nervosa, $30,000; Morrison, Sean (Fellow R. Yue), Damon Runyon Cancer Res Fdn, Functional Analysis of Leptin Receptor Signaling in Hematopoietic Stem Cells and Perivascular Niche, $52,000;

Olson, Eric (Fellow D. Anderson), Amer Heart Assoc, Regulation of IGF-mediated cardiac growth by novel protein encoded at MicroRNA-1-1 and -133a-2 locus, $48,428; Patel, Ashish, Children’s Hosp & Res Ctr at Oakland, S1P Signaling in Inflammatory Bowel Disease, $8,185; Pfeiffer, Julie, Amer Cancer Soc, Ribavirin Uptake as Determinant of HCV Treatment Response, $180,000; Sathe, Meghana, Cystic Fibrosis Fdn, One CF Center: Learning and Leadership Collaborative, $23,760; Scaglioni, Pier, Amer Cancer Soc, Identification of critical components of the K-RAS network in lung cancer, $180,000;

Shay, Jerry (Fellow S. Singel), Susan G. Komen for the Cure, Identify Key Genes in Breast Cancer Genome as Biomarkers of Chemosensitivity or Prognosis, $60,000; Siegelman, Mark, Crohn’s & Colitis Fdn of America, CD44act Dependent Trafficking of Highly Potent Subset of Regulatory T Cells in Human IBD, $115,830; Siegelman, Mark, Amer Diabetes Assoc, Increasing Potent and Specific Autoreactive Treg in Human T1D Using Novel T Cell Adhesion Biomarker CD44act, $103,500; Stowe, Ann, Amer Heart Assoc, B cells mediate endogenous neurovascular protection following stroke, $77,000; Wakeland, Edward, Alliance for Lupus Res, Identifying Functional Variants that Underlie SLE Susceptibility, $190,119;

Willson, James, Amer Cancer Soc, Institutional Research Grant, $210,000; Yanagisawa, Hiromi, Amer Heart Assoc, Role of Fibulin-7, New Member of Fibulin ECM Proteins, in Development and Disease, $80,000; Yin, Helen, Amer Heart Assoc, Estrogen Regulates PIP2 by the Non-Nuclear Pathway to Protect the Endothelium, $70,000; Yu, Hongtao, Clayton Fdn for Res, Development of Next Generation Antimitotic Anticancer Drugs, $300,000; Zhang, Rong (Fellow B. Tseng), Amer Heart Assoc, Exercise Improves Brain Perfusion and Attenuates White Matter Lesions in Ischemic Stroke Survivors - Pilot Study, $50,048.

Industry Sponsored Awards, dollar amounts not available

Amin, Alpesh, Ph3 Trial of Ularitide (Urodilatin) Intravenous Infusion in Pts Suffering from Acute Decompensated Heart Failure (TRUE-AHF); Anderson, Larry, Ph2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Sbjs with Relapsed or Relapsed and Refractory Multiple Myeloma; Frankel, Arthur, The NEMO Trial (NRAS Melanoma and MEK Inhibitor): Ph3 Study of MED162 vs. Dacarbazine in Pts with NRAS Mutation-Positive Melanoma; Frankel, Arthur, Ph3 Study of LGX818 plus MED162 and LGX818 Monotherapy compared with Vemurafenib in Pts with Unresectable or Metastatic BRAF V600 Mutant Melanoma; Gerber, David, Ph2 Study of VS-6063, a Focal Adhesion Kinase (FAK) Inhibitor, in Pts with KRAS Mutant Non-Small Cell Lung Cancer; Haley, Barbara, Phase 1B Study of PD-033299 with T-DM1 for Treatment of Advanced Her2-Positive Breast Cancer;

Hsu, Steven, Acute Venous Thrombosis: thrombus Removal with Adjunctive Catheter-Directed Thrombolysis - ATTRACT Trial - Industry Funds; Hughes, Randall, Study of Chemotherapy Plus Cetuximab in Comb. with YTX-2337 in Pts with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck; Huth, James, Ph3 Study of Dabrafenib (GSK2118436) in Combination with Trametinib (GSK112022) vs. Two Placebos in the Adjuvant Treatment of High-Risk BRAF V600 Mutation-positive Melanoma after Surgical Resection; Jain, Raksha, Two-Period Crossover Study of NM-BL (Burlulipase) in Pts with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis; Jain, Raksha, PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma without Mgmt Methylation: Randomized Ph2 Study; Johnson, Mark, Study of Dabigatran in NVAF Pts with Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy;

Lea, Jayanthi, The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): Ph3 Study of MED162 vs. Physicians Choice Chemotherapy; Lee, Kenneth, Ph3 Study of OTO-201 Single Intratympanic Injection for Intra-Operative Trtmt of Middle Ear Effusion in Ped Subjs Requiring Tympanostomy Tube Placement; Mayo, Marlyn, Ph2b Trial of GS-6624, a Monoclonal Antibody, Against Lysyl Oxidase Like 2 (LOXL2) in Sbjs with Primary Sclerosing Cholangitis (PSC); Mayo, Marlyn, Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for Prevention of Complications in Sbjs with early Decompensated Liver Cirrhosis; Miller, David, Study comparing Yondelis and Doxil / Caelyx with Doxil / Caelyx Monotherapy for treatment of advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer;

Raskin, Philip, Ph3 Study of MK-1293 Compared to Lantus in Sbjs with Type 1 Diabetes Mellitus; Robertson, Danielle, Non-Dispensing Fit Evaluation of etafilcon A Investigational Limbal Ring Contact Lenses with polyvinylpyrrolidone (PVP) in an Asian Population; Sreeramoju, Pranavi, HAI Infection among Surgical and ICU Patients; Wang, Serena, Study of Loteprednol Etabonate Ophthalmic Gel 0.5% vs. Prednisolone Acetate Ophthalmic Suspension 1% for Intraocular Inflammation Following Surgery for Childhood Cataract; Winick, Naomi, Intergroup Trial for Children or Adolescents within B-Cell NHL or B-AL: Evaluation of Rituximab in High Risk Patients.

Share: